Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 10/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312521 | 0.83 | RAB9A (0.46) | NPBWR1MCHR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13225551 | 0.81 | NPC1 (0.53) | NPBWR1MCHR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3321542 | 0.81 | S1PR4 (0.52) | NPBWR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL597464 | 0.81 | HCAR2 (0.43) | NPBWR1MCHR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL16245851 | 0.81 | PKM (0.44) | NPBWR1MCHR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1567467 | 0.81 | NPBWR1 (0.61) | NPBWR1MCHR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20653935 | 0.81 | OXTR (0.42) | NPBWR1MCHR1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL13225552 | 0.80 | NPC1 (0.49) | NPBWR1MCHR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1566534 | 0.80 | MAPK1 (0.54) | SMN1; SMN2NPC1RAB9AMAPTNFKB1 | |
| SCHEMBL3326882 | 0.79 | MTOR (0.39) | NPBWR1MCHR1SMN1; SMN2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155717-B1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8202873-B2 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8115005-B2 | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF. (IS) | 2012-02-14 | — | — | US | disclosed |
| US-8115005-B2 | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF. (IS) | 2012-02-14 | — | — | US | disclosed |
| US-8115005-B2 | Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF. (IS) | 2012-02-14 | — | — | US | disclosed |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20080033013-A1 | PYRAZOLYLPHENYL AND PYRROLYLPHENYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-02-07 | — | — | US | disclosed |
| US-20080033013-A1 | PYRAZOLYLPHENYL AND PYRROLYLPHENYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-02-07 | — | — | US | disclosed |
| US-20080033013-A1 | PYRAZOLYLPHENYL AND PYRROLYLPHENYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-02-07 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | COGAN DEREK | 2007-06-21 | — | — | US | disclosed |
| US-7214802-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1725544-A1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | US | disclosed |
| WO-2005090333-A1 | 3-‘4-HETEROCYCLYL -1,2,3,-TRIAZOL-1-YL!-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033013-A1 | PYRAZOLYLPHENYL AND PYRROLYLPHENYL INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTB4R2, LTC4S, LTA4H | NPBWR1 1374/4885MCHR1 4174/4885SMN1; SMN2 4825/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | NPBWR1 58/4885MCHR1 402/4885SMN1; SMN2 3471/4885 |
| US-20070142371-A1 | Anti-Cytokine Heterocyclic Compounds | TNF, IL6, IL1A | NPBWR1 1453/4885MCHR1 3492/4885SMN1; SMN2 3917/4885 |
| US-20100204278-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | NPBWR1 62/4885MCHR1 324/4885SMN1; SMN2 3956/4885 |
| US-20060079519-A1 | Anti-cytokine heterocyclic compounds | TNF, IL6, IL1A | NPBWR1 1453/4885MCHR1 3492/4885SMN1; SMN2 3917/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | NPBWR1 68/4885MCHR1 354/4885SMN1; SMN2 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.